Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED, savolitinib and surufatinib, will be presented at the ...
Everhope Oncology, a joint venture between Narayana Health, W Health Ventures, and 2070 Health, has raised $10 million in ...
Artificial Intelligence or, AI technology is advancing, and New York is on the forefront of development. RPI partnered up ...
We recently published a list of 10 Stocks Insiders Are Selling In March. In this article, we are going to take a look at ...
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning ...
22hon MSNOpinion
Asbestos is still claiming the lives of many of our veterans nationwide. But there is help now from the Veterans ...
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
TNF inhibitor use demonstrates no negative impact on survival among patients recently diagnosed with colorectal, lung or ...
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
Limited (“HUTCHMED”, the “Company” or “we”) (HKEX:13; Nasdaq/AIM:HCM) today reports its financial results for the year ended December 31, 2024 and provides updates on key clinical and commercial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback